Steward Partners Investment Advisory’s iShares US Small Cap Value Factor ETF SVAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-50
Closed -$1.68K 4463
2025
Q3
$1.68K Hold
50
﹤0.01% 3969
2025
Q2
$1.55K Hold
50
﹤0.01% 3787
2025
Q1
$1.5K Hold
50
﹤0.01% 3700
2024
Q4
$1.62K Hold
50
﹤0.01% 3678
2024
Q3
$1.61K Sell
50
-50
-50% -$1.57K ﹤0.01% 3466
2024
Q2
$2.92K Hold
100
﹤0.01% 3199
2024
Q1
$3.06K Sell
100
-800
-89% -$23.6K ﹤0.01% 3189
2023
Q4
$27.7K Buy
900
+800
+800% +$21.9K ﹤0.01% 2239
2023
Q3
$2.64K Hold
100
﹤0.01% 3027
2023
Q2
$2.67K Hold
100
﹤0.01% 2972
2023
Q1
$2.66K Hold
100
﹤0.01% 2963
2022
Q4
$2.81K Hold
100
﹤0.01% 2941
2022
Q3
$3K Hold
100
﹤0.01% 2974
2022
Q2
$3K Hold
100
﹤0.01% 2949
2022
Q1
$3K Hold
100
﹤0.01% 3042
2021
Q4
$3K Buy
+100
New +$3.16K ﹤0.01% 2967

Other funds holding SVAL

Steward Partners Investment Advisory's SVAL Position: Q4 2025 in Review

Steward Partners Investment Advisory sold out of iShares US Small Cap Value Factor ETF (SVAL) in Q4 2025, closing a stake of 50 shares — an estimated $1.68K sold.

Steward Partners Investment Advisory first reported a position in SVAL in Q4 2021 and held it in 16 quarters. The position peaked at $27.7K in Q4 2023. 30 funds tracked by Wall St. Rank hold SVAL as of Q4 2025.

  • Steward Partners Investment Advisory reported no remaining iShares US Small Cap Value Factor ETF position as of Q4 2025 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 50 iShares US Small Cap Value Factor ETF shares in Q4 2025, an estimated $1.68K.
  • Steward Partners Investment Advisory first reported a position in iShares US Small Cap Value Factor ETF in Q4 2021 and held it in 16 quarters.
  • Steward Partners Investment Advisory's iShares US Small Cap Value Factor ETF position peaked at $27.7K in Q4 2023.
  • 30 funds tracked by Wall St. Rank held iShares US Small Cap Value Factor ETF as of Q4 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2025, filed 12 Feb 2026.